DURECT Corporation - Special Call Transcript
Greetings, and welcome to the DURECT Corporation conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Mike Arenberg, Chief Financial Officer. Please go ahead.
Good afternoon, and welcome to our conference call to discuss the POSIMIR approval. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation.
Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding POSIMIR as well as DURECT's products in development, expected product benefits, regulatory and partnering strategies, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |